---
document_datetime: 2025-11-23 08:05:16
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/introna.html
document_name: introna.html
version: success
processing_time: 0.1093364
conversion_datetime: 2025-12-25 00:02:49.885286
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# IntronA

[RSS](/en/individual-human-medicine.xml/66476)

##### Withdrawn

This medicine's authorisation has been withdrawn

interferon alfa-2b

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 30 November 2021, the European Commission withdrew the marketing authorisation for IntronA (interferon alfa-2b) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Merck Sharp &amp; Dohme B.V., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

IntronA was granted marketing authorisation in the EU on 9 March 2000 for treatment of chronic Hepatitis B, chronic Hepatitis C, hairy cell leukaemia, chronic myelogenous leukaemia, multiple myeloma, follicular lymphoma, carcinoid tumour and malignant melanoma.

The marketing authorisation was initially valid for a 5-year period. It was subsequently renewed for an additional 5-year period in 2005. It was then granted unlimited validity in 2010.

The European Public Assessment Report (EPAR) for IntronA is updated to indicate that the marketing authorisation is no longer valid.

IntronA : EPAR - Summary for the public

English (EN) (707.66 KB - PDF)

**First published:** 10/08/2007

**Last updated:** 14/12/2022

[View](/en/documents/overview/introna-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-631)

български (BG) (814.92 KB - PDF)

**First published:**

10/08/2007

**Last updated:**

14/12/2022

[View](/bg/documents/overview/introna-epar-summary-public_bg.pdf)

español (ES) (712.68 KB - PDF)

**First published:**

10/08/2007

**Last updated:**

14/12/2022

[View](/es/documents/overview/introna-epar-summary-public_es.pdf)

čeština (CS) (772.07 KB - PDF)

**First published:**

10/08/2007

**Last updated:**

14/12/2022

[View](/cs/documents/overview/introna-epar-summary-public_cs.pdf)

dansk (DA) (722.2 KB - PDF)

**First published:**

10/08/2007

**Last updated:**

14/12/2022

[View](/da/documents/overview/introna-epar-summary-public_da.pdf)

Deutsch (DE) (725.34 KB - PDF)

**First published:**

10/08/2007

**Last updated:**

14/12/2022

[View](/de/documents/overview/introna-epar-summary-public_de.pdf)

eesti keel (ET) (125.71 KB - PDF)

**First published:**

10/08/2007

**Last updated:**

14/12/2022

[View](/et/documents/overview/introna-epar-summary-public_et.pdf)

ελληνικά (EL) (825.56 KB - PDF)

**First published:**

10/08/2007

**Last updated:**

14/12/2022

[View](/el/documents/overview/introna-epar-summary-public_el.pdf)

français (FR) (713.57 KB - PDF)

**First published:**

10/08/2007

**Last updated:**

14/12/2022

[View](/fr/documents/overview/introna-epar-summary-public_fr.pdf)

italiano (IT) (711.72 KB - PDF)

**First published:**

10/08/2007

**Last updated:**

14/12/2022

[View](/it/documents/overview/introna-epar-summary-public_it.pdf)

latviešu valoda (LV) (784.16 KB - PDF)

**First published:**

10/08/2007

**Last updated:**

14/12/2022

[View](/lv/documents/overview/introna-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (719.84 KB - PDF)

**First published:**

10/08/2007

**Last updated:**

14/12/2022

[View](/lt/documents/overview/introna-epar-summary-public_lt.pdf)

magyar (HU) (790.79 KB - PDF)

**First published:**

10/08/2007

**Last updated:**

14/12/2022

[View](/hu/documents/overview/introna-epar-summary-public_hu.pdf)

Malti (MT) (776.14 KB - PDF)

**First published:**

10/08/2007

**Last updated:**

14/12/2022

[View](/mt/documents/overview/introna-epar-summary-public_mt.pdf)

Nederlands (NL) (723.69 KB - PDF)

**First published:**

10/08/2007

**Last updated:**

14/12/2022

[View](/nl/documents/overview/introna-epar-summary-public_nl.pdf)

polski (PL) (782.03 KB - PDF)

**First published:**

10/08/2007

**Last updated:**

14/12/2022

[View](/pl/documents/overview/introna-epar-summary-public_pl.pdf)

português (PT) (730.68 KB - PDF)

**First published:**

10/08/2007

**Last updated:**

14/12/2022

[View](/pt/documents/overview/introna-epar-summary-public_pt.pdf)

română (RO) (723.2 KB - PDF)

**First published:**

10/08/2007

**Last updated:**

14/12/2022

[View](/ro/documents/overview/introna-epar-summary-public_ro.pdf)

slovenčina (SK) (771.68 KB - PDF)

**First published:**

10/08/2007

**Last updated:**

14/12/2022

[View](/sk/documents/overview/introna-epar-summary-public_sk.pdf)

slovenščina (SL) (779.08 KB - PDF)

**First published:**

10/08/2007

**Last updated:**

14/12/2022

[View](/sl/documents/overview/introna-epar-summary-public_sl.pdf)

Suomi (FI) (708.53 KB - PDF)

**First published:**

10/08/2007

**Last updated:**

14/12/2022

[View](/fi/documents/overview/introna-epar-summary-public_fi.pdf)

svenska (SV) (718.99 KB - PDF)

**First published:**

10/08/2007

**Last updated:**

14/12/2022

[View](/sv/documents/overview/introna-epar-summary-public_sv.pdf)

## Product information

IntronA : EPAR - Product Information

English (EN) (4.82 MB - PDF)

**First published:** 01/04/2009

**Last updated:** 14/12/2022

[View](/en/documents/product-information/introna-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-492)

български (BG) (9.29 MB - PDF)

**First published:**

01/04/2009

**Last updated:**

14/12/2022

[View](/bg/documents/product-information/introna-epar-product-information_bg.pdf)

español (ES) (5.16 MB - PDF)

**First published:**

01/04/2009

**Last updated:**

14/12/2022

[View](/es/documents/product-information/introna-epar-product-information_es.pdf)

čeština (CS) (7.82 MB - PDF)

**First published:**

01/04/2009

**Last updated:**

14/12/2022

[View](/cs/documents/product-information/introna-epar-product-information_cs.pdf)

dansk (DA) (5.01 MB - PDF)

**First published:**

01/04/2009

**Last updated:**

14/12/2022

[View](/da/documents/product-information/introna-epar-product-information_da.pdf)

Deutsch (DE) (5.41 MB - PDF)

**First published:**

01/04/2009

**Last updated:**

14/12/2022

[View](/de/documents/product-information/introna-epar-product-information_de.pdf)

eesti keel (ET) (5.06 MB - PDF)

**First published:**

01/04/2009

**Last updated:**

14/12/2022

[View](/et/documents/product-information/introna-epar-product-information_et.pdf)

ελληνικά (EL) (10.03 MB - PDF)

**First published:**

01/04/2009

**Last updated:**

14/12/2022

[View](/el/documents/product-information/introna-epar-product-information_el.pdf)

français (FR) (5.43 MB - PDF)

**First published:**

01/04/2009

**Last updated:**

14/12/2022

[View](/fr/documents/product-information/introna-epar-product-information_fr.pdf)

hrvatski (HR) (4.83 MB - PDF)

**First published:**

01/04/2009

**Last updated:**

14/12/2022

[View](/hr/documents/product-information/introna-epar-product-information_hr.pdf)

íslenska (IS) (5.17 MB - PDF)

**First published:**

01/04/2009

**Last updated:**

14/12/2022

[View](/is/documents/product-information/introna-epar-product-information_is.pdf)

italiano (IT) (5.26 MB - PDF)

**First published:**

01/04/2009

**Last updated:**

14/12/2022

[View](/it/documents/product-information/introna-epar-product-information_it.pdf)

latviešu valoda (LV) (7.91 MB - PDF)

**First published:**

01/04/2009

**Last updated:**

14/12/2022

[View](/lv/documents/product-information/introna-epar-product-information_lv.pdf)

lietuvių kalba (LT) (4.65 MB - PDF)

**First published:**

01/04/2009

**Last updated:**

14/12/2022

[View](/lt/documents/product-information/introna-epar-product-information_lt.pdf)

magyar (HU) (8.81 MB - PDF)

**First published:**

01/04/2009

**Last updated:**

14/12/2022

[View](/hu/documents/product-information/introna-epar-product-information_hu.pdf)

Malti (MT) (8.73 MB - PDF)

**First published:**

01/04/2009

**Last updated:**

14/12/2022

[View](/mt/documents/product-information/introna-epar-product-information_mt.pdf)

Nederlands (NL) (5.18 MB - PDF)

**First published:**

01/04/2009

**Last updated:**

14/12/2022

[View](/nl/documents/product-information/introna-epar-product-information_nl.pdf)

norsk (NO) (5.02 MB - PDF)

**First published:**

01/04/2009

**Last updated:**

14/12/2022

[View](/no/documents/product-information/introna-epar-product-information_no.pdf)

polski (PL) (8.43 MB - PDF)

**First published:**

01/04/2009

**Last updated:**

14/12/2022

[View](/pl/documents/product-information/introna-epar-product-information_pl.pdf)

português (PT) (5.56 MB - PDF)

**First published:**

01/04/2009

**Last updated:**

14/12/2022

[View](/pt/documents/product-information/introna-epar-product-information_pt.pdf)

română (RO) (4.63 MB - PDF)

**First published:**

01/04/2009

**Last updated:**

14/12/2022

[View](/ro/documents/product-information/introna-epar-product-information_ro.pdf)

slovenčina (SK) (8.43 MB - PDF)

**First published:**

01/04/2009

**Last updated:**

14/12/2022

[View](/sk/documents/product-information/introna-epar-product-information_sk.pdf)

slovenščina (SL) (8.25 MB - PDF)

**First published:**

01/04/2009

**Last updated:**

14/12/2022

[View](/sl/documents/product-information/introna-epar-product-information_sl.pdf)

Suomi (FI) (5.03 MB - PDF)

**First published:**

01/04/2009

**Last updated:**

14/12/2022

[View](/fi/documents/product-information/introna-epar-product-information_fi.pdf)

svenska (SV) (5.12 MB - PDF)

**First published:**

01/04/2009

**Last updated:**

14/12/2022

[View](/sv/documents/product-information/introna-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0122 10/06/2021

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

IntronA : EPAR - All Authorised presentations

English (EN) (685.57 KB - PDF)

**First published:** 11/08/2006

**Last updated:** 14/12/2022

[View](/en/documents/all-authorised-presentations/introna-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-992)

български (BG) (792.03 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

14/12/2022

[View](/bg/documents/all-authorised-presentations/introna-epar-all-authorised-presentations_bg.pdf)

español (ES) (709.45 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

14/12/2022

[View](/es/documents/all-authorised-presentations/introna-epar-all-authorised-presentations_es.pdf)

čeština (CS) (793.64 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

14/12/2022

[View](/cs/documents/all-authorised-presentations/introna-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (707.49 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

14/12/2022

[View](/da/documents/all-authorised-presentations/introna-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (702.37 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

14/12/2022

[View](/de/documents/all-authorised-presentations/introna-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (66.51 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

14/12/2022

[View](/et/documents/all-authorised-presentations/introna-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (838.21 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

14/12/2022

[View](/el/documents/all-authorised-presentations/introna-epar-all-authorised-presentations_el.pdf)

français (FR) (684.93 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

14/12/2022

[View](/fr/documents/all-authorised-presentations/introna-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (691.85 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

14/12/2022

[View](/hr/documents/all-authorised-presentations/introna-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (687.86 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

14/12/2022

[View](/is/documents/all-authorised-presentations/introna-epar-all-authorised-presentations_is.pdf)

italiano (IT) (705.08 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

14/12/2022

[View](/it/documents/all-authorised-presentations/introna-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (801.72 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

14/12/2022

[View](/lv/documents/all-authorised-presentations/introna-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (682.42 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

14/12/2022

[View](/lt/documents/all-authorised-presentations/introna-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (769.93 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

14/12/2022

[View](/hu/documents/all-authorised-presentations/introna-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (834.18 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

14/12/2022

[View](/mt/documents/all-authorised-presentations/introna-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (692.71 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

14/12/2022

[View](/nl/documents/all-authorised-presentations/introna-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (689.29 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

14/12/2022

[View](/no/documents/all-authorised-presentations/introna-epar-all-authorised-presentations_no.pdf)

polski (PL) (768.94 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

14/12/2022

[View](/pl/documents/all-authorised-presentations/introna-epar-all-authorised-presentations_pl.pdf)

português (PT) (703.81 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

14/12/2022

[View](/pt/documents/all-authorised-presentations/introna-epar-all-authorised-presentations_pt.pdf)

română (RO) (698.6 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

14/12/2022

[View](/ro/documents/all-authorised-presentations/introna-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (768.87 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

14/12/2022

[View](/sk/documents/all-authorised-presentations/introna-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (750.04 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

14/12/2022

[View](/sl/documents/all-authorised-presentations/introna-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (686.46 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

14/12/2022

[View](/fi/documents/all-authorised-presentations/introna-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (685.94 KB - PDF)

**First published:**

11/08/2006

**Last updated:**

14/12/2022

[View](/sv/documents/all-authorised-presentations/introna-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine IntronA Active substance interferon alfa-2b International non-proprietary name (INN) or common name interferon alfa-2b Therapeutic area (MeSH)

- Carcinoid Tumor
- Leukemia, Hairy Cell
- Lymphoma, Follicular
- Hepatitis B, Chronic
- Hepatitis C, Chronic
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Melanoma
- Multiple Myeloma

Anatomical therapeutic chemical (ATC) code L03AB05

### Pharmacotherapeutic group

Immunostimulants

### Therapeutic indication

**Chronic hepatitis B**

Treatment of adult patients with chronic hepatitis B associated with evidence of hepatitis-B viral replication (presence of DNA of hepatitis-B virus (HBV-DNA) and hepatitis-B antigen (HBeAg), elevated alanine aminotransferase (ALT) and histologically proven active liver inflammation and / or fibrosis.

**Chronic hepatitis C**

Before initiating treatment with IntronA, consideration should be given to the results from clinical trials comparing IntronA with pegylated interferon.

*Adult patients*

IntronA is indicated for the treatment of adult patients with chronic hepatitis C who have elevated transaminases without liver decompensation and who are positive for hepatitis-C virus-RNA (HCV-RNA).

The best way to use IntronA in this indication is in combination with ribavirin.

*Children three years of age and older and adolescents*

IntronA is indicated, in a combination regimen with ribavirin, for the treatment of children three years of age and older and adolescents, who have chronic hepatitis C, not previously treated, without liver decompensation, and who are positive for HCV-RNA. When deciding not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition that resulted in reduced final adult height in some patients.

The decision to treat should be made on a case-by-case basis.

**Hairy-cell leukaemia**

Treatment of patients with hairy cell leukaemia.

**Chronic myelogenous leukaemia**

*Monotherapy*

Treatment of adult patients with Philadelphia-chromosome- or bcr/abl-translocation-positive chronic myelogenous leukaemia.

Clinical experience indicates that a haematological and cytogenetic major / minor response is obtainable in the majority of patients treated. A major cytogenetic response is defined by &lt; 34 % Ph+ leukaemic cells in the bone marrow, whereas a minor response is ? 34 %, but &lt; 90 % Ph+ cells in the marrow.

*Combination therapy*

The combination of interferon alfa-2b and cytarabine (Ara-C) administered during the first 12 months of treatment has been demonstrated to significantly increase the rate of major cytogenetic responses and to significantly prolong the overall survival at three years when compared to interferon alfa-2b monotherapy.

**Multiple myeloma**

As maintenance therapy in patients who have achieved objective remission (more than 50% reduction in myeloma protein) following initial induction chemotherapy.

Current clinical experience indicates that maintenance therapy with interferon alfa-2b prolongs the plateau phase; however, effects on overall survival have not been conclusively demonstrated.

**Follicular lymphoma**

Treatment of high-tumour-burden follicular lymphoma as adjunct to appropriate combination induction chemotherapy such as a CHOP-like regimen. High tumour burden is defined as having at least one of the following: bulky tumour mass (&gt; 7 cm), involvement of three or more nodal sites (each &gt; 3 cm), systemic symptoms (weight loss &gt; 10 %, pyrexia &gt; 38°C for more than eight days, or nocturnal sweats), splenomegaly beyond the umbilicus, major organ obstruction or compression syndrome, orbital or epidural involvement, serous effusion, or leukaemia.

**Carcinoid tumour**

Treatment of carcinoid tumours with lymph node or liver metastases and with 'carcinoid syndrome'.

**Malignant melanoma**

As adjuvant therapy in patients who are free of disease after surgery but are at high risk of systemic recurrence, e.g. patients with primary or recurrent (clinical or pathological) lymph-node.

## Authorisation details

EMA product number EMEA/H/C/000281 Marketing authorisation holder

Merck Sharp &amp; Dohme B.V.

Waarderweg 39

Marketing authorisation issued 09/03/2000 Revision 34

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

IntronA : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (1.14 MB - PDF)

**First published:** 25/03/2009

**Last updated:** 15/12/2022

[View](/en/documents/procedural-steps-after/introna-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

IntronA -H-C-PSUSA-00001758-201609: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/671966/2017

English (EN) (642.61 KB - PDF)

**First published:** 11/10/2017

**Last updated:** 14/12/2022

[View](/en/documents/scientific-conclusion/introna-h-c-psusa-00001758-201609-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

IntronA : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (682.15 KB - PDF)

**First published:** 11/08/2006

**Last updated:** 14/12/2022

[View](/en/documents/steps-after-cutoff/introna-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

IntronA : EPAR - Scientific Discussion

English (EN) (1 MB - PDF)

**First published:** 11/08/2006

**Last updated:** 14/12/2022

[View](/en/documents/scientific-discussion/introna-epar-scientific-discussion_en.pdf)

IntronA : EPAR - Procedural steps taken before authorisation

English (EN) (672.08 KB - PDF)

**First published:** 11/08/2006

**Last updated:** 15/12/2022

[View](/en/documents/procedural-steps/introna-epar-procedural-steps-taken-authorisation_en.pdf)

**This page was last updated on** 15/12/2022

## Share this page

[Back to top](#main-content)